TITLE

Intl Stem Cell Corp Completes $5 Mln Financing and Elects Jim Berglund to the Board of Directors

PUB. DATE
March 2012
SOURCE
Biomedical Market Newsletter;3/14/2012, Vol. 21, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that International Stem Cell Corp. (ISCO) had obtained new capital financing of five million dollars in issued series of G Convertible Preferred Stock. It is mentioned that this financing was made by Andrey Semechkin, chief executive officer of ISCO. It further states that James Berglund has been appointed to Board of Directors of the company in place of Kenneth C. Aldrich.
ACCESSION #
75259039

 

Related Articles

  • International Stem Cell Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells.  // Biomedical Market Newsletter;6/19/2011, p758 

    The article discusses the discovery of a technology by the scientists at International Stem Cell Corp. (ISCO) which helps produce liver cells uncontaminated with undifferentiated cells. It says that the starting materials for liver cells production are pluripotent stem cells, either human...

  • Intl Stem Cell Corp Announces 3rd Qtr 2011 Financial Results.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p789 

    The article reports on the 2011 third quarter financial performance of International Stem Cell Corp. (ISCO) which declares a revenue of 0.84 million dollars for the quarter. It states that increases in revenue was strongly motivated by strong sales from the initial launch of ISCO's wholly-owned...

  • International Stem Cell Corp Announces Changes to Streamline Management Team.  // Biomedical Market Newsletter;5/16/2011, p74 

    The article reports on the management changes at International Stem Cell Corp. (ISCO). It states that Brian Lundstrom has entered into a new contract which allows him to exclusively focus on therapeutic development and international partnering programs in areas outside the U.S. such as China and...

  • At-the-Market Financing Facility Secures ISCO $25M. Shaffer, Catherine // BioWorld Today;12/14/2010, Vol. 21 Issue 240, p1 

    The article reports on Aspire Capital Fund LLC's purchase of shares of International Stem Cell Corp. The agreement covers a financing facility that will permit Aspire to acquire up to 25 million U.S. dollars in equity capital. Companies such as Bionovo Inc. and Dynavax Technologies Corp. have...

  • Financings roundup.  // Medical Device Daily;8/22/2008, Vol. 12 Issue 182, p5 

    The article reports that International Stem Cell entered into a subscription agreement with an accredited investor to sell $3 million of Series C preferred stock at a price of $1 per share. The funding is to occur in three tranches, including the first, which closed on August 20, 2008 for...

  • The best defense is a good defense. Osterland, Andrew // Financial World;3/25/96, Vol. 165 Issue 5, p18 

    Reports on the performance of pharmaceutical stocks in the United States as of March 1996. Outperformance of the Standard & Poor's 500 index; Estimated annual growth of earnings in the pharmaceuticals sector; Value tier of the industry as projected by J.P. Morgan analyst Steve Tighe;...

  • One way to make up to 57% investing in drug companies. Sloan, Allan // Money;Oct94, Vol. 23 Issue 10, p27 

    Advises on buying drug company stocks. Drug companies' loss of pricing power to mass buyers of health-care products; Advice to invest in drug companies with the least promising prospects; Promising stock prices of lagging companies as they are gobbled up by big companies; Cases.

  • Stock Movers.  // BioWorld Today;1/27/2012, Vol. 23 Issue 18, p2 

    A table is presented which lists the stock movers among pharmaceutical companies as of January 26, 2012 including Nasdaq Biotechnology, BioLineRx Ltd. and Geron Corp.

  • International Stem Cell Gets Parthenogenetic Patent. Chambers, Heather // San Diego Business Journal;6/14/2010, Vol. 31 Issue 24, p6 

    The article reports on the potential of the International Stem Cell Corp. in Oceanside, California, to receive a patent related to the development of human parthenogenetic stem cells.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics